Literature DB >> 26303775

Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials.

Igor Sorokin1, Adam Schatz, Charles Welliver.   

Abstract

Placebo medications and sham surgeries have long been thought to be inert treatments. These groups served as a threshold to which an active treatment should be compared in a randomized trial to determine the true efficacy of the active treatment. However, surprising changes in subjective symptom scores and objective measures of voiding have been demonstrated in numerous placebo medication or sham surgery arms of trials. The exact mechanisms by which these inactive treatments augment patient outcomes are not clearly defined and multiple theories have been proposed to explain the often pronounced response. It appears that urologic outcomes are particularly prone to these effects and the astute physician should keep these responses in mind when interpreting any trial on a new therapy.

Entities:  

Mesh:

Year:  2015        PMID: 26303775     DOI: 10.1007/s11934-015-0544-4

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  65 in total

1.  Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.

Authors:  M Andersen; C Dahlstrand; K Høye
Journal:  Eur Urol       Date:  2000-10       Impact factor: 20.096

2.  Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.

Authors:  Yanqun Na; Zhangqun Ye; Shanzhong Zhang
Journal:  Clin Drug Investig       Date:  2012-01-01       Impact factor: 2.859

3.  The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring.

Authors:  S M Sech; J D Montoya; P A Bernier; E Barnboym; S Brown; A Gregory; C G Roehrborn
Journal:  Urology       Date:  1998-02       Impact factor: 2.649

Review 4.  Clinically and Statistically Significant Changes Seen in Sham Surgery Arms of Randomized, Controlled Benign Prostatic Hyperplasia Surgery Trials.

Authors:  Charles Welliver; Michael Kottwitz; Paul Feustel; Kevin McVary
Journal:  J Urol       Date:  2015-07-02       Impact factor: 7.450

5.  Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia.

Authors:  Mostafa M Elhilali; Peter Pommerville; Richard C Yocum; Rosemina Merchant; Claus G Roehrborn; Samuel R Denmeade
Journal:  J Urol       Date:  2012-11-07       Impact factor: 7.450

6.  Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial.

Authors:  C G Roehrborn; G Preminger; P Newhall; J Denstedt; H Razvi; L J Chin; A Perlmutter; W Barzell; W Whitmore; R Fritzsch; J Sanders; S Sech; S Womack
Journal:  Urology       Date:  1998-01       Impact factor: 2.649

7.  Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial.

Authors:  A S Bdesha; C J Bunce; J P Kelleher; M E Snell; J Vukusic; R O Witherow
Journal:  BMJ       Date:  1993-05-15

8.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

9.  Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar.

Authors:  C A Byrnes; A S Morton; C L Liss; M C Lippert; J Y Gillenwater
Journal:  Clin Ther       Date:  1995 Sep-Oct       Impact factor: 3.393

10.  The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials--a secondary analysis.

Authors:  Harald Walach; Catarina Sadaghiani; Cornelia Dehm; Dick Bierman
Journal:  BMC Med Res Methodol       Date:  2005-08-18       Impact factor: 4.615

View more
  5 in total

1.  Informed consent and clinical trials: where is the placebo effect?

Authors:  C R Blease; F L Bishop; T J Kaptchuk
Journal:  BMJ       Date:  2017-02-03

Review 2.  Placebo Effects in Traumatic Brain Injury.

Authors:  Ginger Polich; Mary Alexis Iaccarino; Ted J Kaptchuk; Leon Morales-Quezada; Ross Zafonte
Journal:  J Neurotrauma       Date:  2018-04-05       Impact factor: 5.269

Review 3.  The placebo and nocebo effects in functional urology.

Authors:  Hadi Mostafaei; Sandra Jilch; Greta Lisa Carlin; Keiichiro Mori; Fahad Quhal; Benjamin Pradere; Ekaterina Laukhtina; Victor M Schuettfort; Abdulmajeed Aydh; Reza Sari Motlagh; Claus G Roehrborn; Shahrokh F Shariat; Sakineh Hajebrahimi
Journal:  Nat Rev Urol       Date:  2021-12-23       Impact factor: 14.432

4.  Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia.

Authors:  Christopher M Dixon; Edwin Rijo Cedano; Dalibor Pacik; Vítězslav Vit; Gabriel Varga; Lennart Wagrell; Thayne R Larson; Lance A Mynderse
Journal:  Res Rep Urol       Date:  2016-11-21

5.  Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial.

Authors:  Sarah Ballou; Ted J Kaptchuk; William Hirsch; Judy Nee; Johanna Iturrino; Kathryn T Hall; John M Kelley; Vivian Cheng; Irving Kirsch; Eric Jacobson; Lisa Conboy; Anthony Lembo; Roger B Davis
Journal:  Trials       Date:  2017-05-25       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.